Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_4
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

unknown267%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer

NCT04889820
unknownphase_2

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

NCT03053856
unknownphase_4

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

NCT02281266

Clinical Trials (3)

Showing 3 of 3 trials
NCT04889820Not Applicable

Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer

Not Yet Recruiting
NCT03053856Phase 2

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

Unknown
NCT02281266Phase 4

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Unknown

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3